Skip to main content
Thank you for visiting nature.com. You are using a browser version
with limited support for CSS. To obtain the best experience, we
recommend you use a more up to date browser (or turn off
compatibility mode in Internet Explorer). In the meantime, to
ensure continued support, we are displaying the site without styles
and JavaScript.
Advertisement
[image]
[image]
•  View all journals
•  
Search
•  Log in
•  Content Explore content
•  About the journal
•  Publish with us
•  Subscribe
•  Sign up for alerts
•  RSS feed
1. nature 
2. articles 
3. article
Show authors
•  Article
•  Published: 02 August 2017


Correction of a pathogenic
gene mutation in human
embryos
•  Hong Ma1 na1,
•  Nuria Marti-Gutierrez1 na1,
•  Sang-Wook Park2 na1,
•  Jun Wu3 na1,
•  Yeonmi Lee1,
•  Keiichiro Suzuki3,
•  Amy Koski1,
•  Dongmei Ji1,
•  Tomonari Hayama1,
•  Riffat Ahmed1,
•  Hayley Darby1,
•  Crystal Van Dyken1,
•  Ying Li1,
•  Eunju Kang1,
•  A.-Reum Park2,
•  Daesik Kim4,
•  Sang-Tae Kim2,
•  Jianhui Gong5,6,7,8,
•  Ying Gu5,6,7,
•  Xun Xu5,6,7,
•  David Battaglia1,9,
•  Sacha A. Krieg9,
•  David M. Lee9,
•  Diana H. Wu9,
•  Don P. Wolf1,
•  Stephen B. Heitner10,
•  Juan Carlos Izpisua Belmonte
3 na2,
•  Paula Amato
1,9 na2,
•  Jin-Soo Kim
2,4 na2,
•  Sanjiv Kaul
10 na2 &
•  …
•  Shoukhrat Mitalipov
1,10 na2 


Nature volume 548, pages 413–419 (2017)Cite this article
•  358k Accesses
•  886 Citations
•  4222 Altmetric
•  Metrics details
Subjects
•  Embryology
•  Medical genetics
A Brief Communications Arising to this article was published on 08
August 2018
A Brief Communications Arising to this article was published on 08
August 2018
This article has been updated
Abstract
Genome editing has potential for the targeted correction of
germline mutations. Here we describe the correction of the
heterozygous MYBPC3 mutation in human preimplantation embryos
with precise CRISPR–Cas9-based targeting accuracy and high
homology-directed repair efficiency by activating an endogenous,
germline-specific DNA repair response. Induced double-strand
breaks (DSBs) at the mutant paternal allele were predominantly
repaired using the homologous wild-type maternal gene instead of a


synthetic DNA template. By modulating the cell cycle stage at
which the DSB was induced, we were able to avoid mosaicism in
cleaving embryos and achieve a high yield of homozygous embryos
carrying the wild-type MYBPC3 gene without evidence of off-target
mutations. The efficiency, accuracy and safety of the approach
presented suggest that it has potential to be used for the correction
of heritable mutations in human embryos by complementing
preimplantation genetic diagnosis. However, much remains to be
considered before clinical applications, including the reproducibility
of the technique with other heterozygous mutations.
 Access through your institution
Buy or subscribe
This is a preview of subscription content, access via your institution
Access options
 Access through your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Learn more
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Learn more
Buy this article


•  Purchase on SpringerLink
•  Instant access to full article PDF
Buy now
Prices may be subject to local taxes which are calculated during
checkout
Additional access options:
•  Log in
•  Learn about institutional subscriptions
•  Read our FAQs
•  Contact customer support
Figure 1: Gene correction in S-phase-injected human embryos.
[image]
Figure 2: Gene targeting and HDR efficiency in S-phase-injected
human embryos.
[image]
Figure 3: Gene correction in M-phase-injected human embryos.
[image]
Figure 4: Preimplantation development of CRISPR–Cas9-
injected embryos.
[image]
Similar content being viewed by others
[image]
Limitations of gene editing assessments in human
preimplantation embryos
Article Open access 07 March 2023
[image]
Single-cell multi-omics profiling of human
preimplantation embryos identifies cytoskeletal
defects during embryonic arrest


Article 18 January 2024
[image]
Genome-coverage single-cell histone modifications for
embryo lineage tracing
Article Open access 26 February 2025
Change history
•  
02 October 2017
Editorial Note: Readers are alerted that some of the
conclusions of this paper are subject to critiques that are
being considered by editors. Some of these critiques have
been publicly deposited in preprint form. A further editorial
response will follow the resolution of these issues.
References
1. Antoniou, A. et al. Average risks of breast and ovarian cancer
associated with BRCA1 or BRCA2 mutations detected in case
series unselected for family history: a combined analysis of 22
studies. Am. J. Hum. Genet. 72, 1117–1130 (2003)
CAS  PubMed  PubMed Central  Google Scholar 
2. Carrier, L., Mearini, G., Stathopoulou, K. & Cuello, F. Cardiac
myosin-binding protein C (MYBPC3) in cardiac
pathophysiology. Gene 573, 188–197 (2015)
CAS  PubMed  PubMed Central  Google Scholar 
3. Dhandapany, P. S. et al. A common MYBPC3 (cardiac myosin
binding protein C) variant associated with cardiomyopathies
in South Asia. Nat. Genet. 41, 187–191 (2009)


CAS  PubMed  PubMed Central  Google Scholar 
4. Struewing, J. P. et al. The risk of cancer associated with
specific mutations of BRCA1 and BRCA2 among Ashkenazi
Jews. N. Engl. J. Med. 336, 1401–1408 (1997)
CAS  PubMed  Google Scholar 
5. Maron, B. J. et al. Prevalence of hypertrophic
cardiomyopathy in a general population of young adults.
Echocardiographic analysis of 4111 subjects in the CARDIA
Study. Circulation 92, 785–789 (1995)
CAS  PubMed  Google Scholar 
6. Schlossarek, S., Mearini, G. & Carrier, L. Cardiac myosin-
binding protein C in hypertrophic cardiomyopathy:
mechanisms and therapeutic opportunities. J. Mol. Cell.
Cardiol. 50, 613–620 (2011)
CAS  PubMed  Google Scholar 
7. Hsu, P. D., Lander, E. S. & Zhang, F. Development and
applications of CRISPR–Cas9 for genome engineering. Cell
157, 1262–1278 (2014)
CAS  PubMed  PubMed Central  Google Scholar 
8. Mali, P. et al. RNA-guided human genome engineering via
Cas9. Science 339, 823–826 (2013)
ADS  CAS  PubMed  PubMed Central  Google Scholar 
9. Kim, S., Kim, D., Cho, S. W., Kim, J. & Kim, J. S. Highly
efficient RNA-guided genome editing in human cells via
delivery of purified Cas9 ribonucleoproteins. Genome Res. 24,
1012–1019 (2014)
Article  CAS  PubMed  PubMed Central  Google Scholar 
10. Cong, L. et al. Multiplex genome engineering using CRISPR/
Cas systems. Science 339, 819–823 (2013)


ADS  CAS  PubMed  PubMed Central  Google Scholar 
11. Lin, S., Staahl, B. T., Alla, R. K. & Doudna, J. A. Enhanced
homology-directed human genome engineering by controlled
timing of CRISPR/Cas9 delivery. eLife 3, e04766 (2014)
PubMed  PubMed Central  Google Scholar 
12. Wu, Y. et al. Correction of a genetic disease in mouse via use
of CRISPR–Cas9. Cell Stem Cell 13, 659–662 (2013)
CAS  PubMed  Google Scholar 
13. Guo, X. & Li, X. J. Targeted genome editing in primate
embryos. Cell Res. 25, 767–768 (2015)
ADS  CAS  PubMed  PubMed Central  Google Scholar 
14. Wang, H. et al. One-step generation of mice carrying
mutations in multiple genes by CRISPR/Cas-mediated genome
engineering. Cell 153, 910–918 (2013)
CAS  PubMed  PubMed Central  Google Scholar 
15. Kang, E. et al. Age-related accumulation of somatic
mitochondrial DNA mutations in adult-derived human iPSCs.
Cell Stem Cell 18, 625–636 (2016)
CAS  PubMed  Google Scholar 
16. Cho, S. W., Kim, S., Kim, J. M. & Kim, J. S. Targeted genome
engineering in human cells with the Cas9 RNA-guided
endonuclease. Nat. Biotechnol. 31, 230–232 (2013)
CAS  PubMed  Google Scholar 
17. Kim, H. & Kim, J. S. A guide to genome engineering with
programmable nucleases. Nat. Rev. Genet. 15, 321–334 (2014)
CAS  PubMed  Google Scholar 
18. Jinek, M. et al. A programmable dual-RNA-guided DNA


endonuclease in adaptive bacterial immunity. Science 337,
816–821 (2012)
ADS  CAS  PubMed  PubMed Central  Google Scholar 
19. Aida, T. et al. Cloning-free CRISPR/Cas system facilitates
functional cassette knock-in in mice. Genome Biol. 16, 87
(2015)
PubMed  PubMed Central  Google Scholar 
20. Capmany, G., Taylor, A., Braude, P. R. & Bolton, V. N. The
timing of pronuclear formation, DNA synthesis and cleavage
in the human 1-cell embryo. Mol. Hum. Reprod. 2, 299–306
(1996)
CAS  PubMed  Google Scholar 
21. Suzuki, T., Asami, M. & Perry, A. C. Asymmetric parental
genome engineering by Cas9 during mouse meiotic exit. Sci.
Rep. 4, 7621 (2014)
ADS  CAS  PubMed  PubMed Central  Google Scholar 
22. Fu, Y. et al. High-frequency off-target mutagenesis induced by
CRISPR–Cas nucleases in human cells. Nat. Biotechnol. 31,
822–826 (2013)
CAS  PubMed  PubMed Central  Google Scholar 
23. Hsu, P. D. et al. DNA targeting specificity of RNA-guided Cas9
nucleases. Nat. Biotechnol. 31, 827–832 (2013)
CAS  PubMed  PubMed Central  Google Scholar 
24. Cho, S. W. et al. Analysis of off-target effects of CRISPR/Cas-
derived RNA-guided endonucleases and nickases. Genome Res.
24, 132–141 (2014)
CAS  PubMed  PubMed Central  Google Scholar 
25. Kim, D. et al. Digenome-seq: genome-wide profiling of


CRISPR–Cas9 off-target effects in human cells. Nat. Methods
12, 237–243 (2015)
CAS  PubMed  Google Scholar 
26. Kim, D., Kim, S., Kim, S., Park, J. & Kim, J. S. Genome-wide
target specificities of CRISPR–Cas9 nucleases revealed by
multiplex Digenome-seq. Genome Res. 26, 406–415 (2016)
CAS  PubMed  PubMed Central  Google Scholar 
27. Robinson, J. T. et al. Integrative genomics viewer. Nat.
Biotechnol. 29, 24–26 (2011)
CAS  PubMed  PubMed Central  Google Scholar 
28. Schneider, T. D. & Stephens, R. M. Sequence logos: a new way
to display consensus sequences. Nucleic Acids Res. 18, 6097–
6100 (1990)
Article  CAS  PubMed  PubMed Central  Google Scholar 
29. Tennakoon, C., Purbojati, R. W. & Sung, W. K. BatMis: a fast
algorithm for k-mismatch mapping. Bioinformatics 28, 2122–
2128 (2012)
CAS  PubMed  Google Scholar 
30. Richardson, C. D., Ray, G. J., DeWitt, M. A., Curie, G. L. &
Corn, J. E. Enhancing homology-directed genome editing by
catalytically active and inactive CRISPR–Cas9 using
asymmetric donor DNA. Nat. Biotechnol. 34, 339–344 (2016)
CAS  PubMed  Google Scholar 
31. Doudna, J. A. & Charpentier, E. The new frontier of genome
engineering with CRISPR–Cas9. Science 346, 1258096 (2014)
PubMed  Google Scholar 
32. Luo, Y. et al. Hypersensitivity of primordial germ cells to
compromised replication-associated DNA repair involves


ATM-p53-p21 signaling. PLoS Genet. 10, e1004471 (2014)
PubMed  PubMed Central  Google Scholar 
33. Lange, J. et al. The landscape of mouse meiotic double-strand
break formation, processing, and repair. Cell 167, 695–708
(2016)
CAS  PubMed  PubMed Central  Google Scholar 
34. Titus, S. et al. Impairment of BRCA1-related DNA double-
strand break repair leads to ovarian aging in mice and
humans. Sci. Transl. Med. 5, 172ra21 (2013)
PubMed  PubMed Central  Google Scholar 
35. Tang, L. et al. CRISPR/Cas9-mediated gene editing in human
zygotes using Cas9 protein. Mol. Genet. Genomics 292, 525–
533 (2017)
CAS  PubMed  Google Scholar 
36. Chu, V. T. et al. Increasing the efficiency of homology-
directed repair for CRISPR–Cas9-induced precise gene editing
in mammalian cells. Nat. Biotechnol. 33, 543–548 (2015)
CAS  PubMed  Google Scholar 
37. Maruyama, T. et al. Increasing the efficiency of precise
genome editing with CRISPR–Cas9 by inhibition of
nonhomologous end joining. Nat. Biotechnol. 33, 538–542
(2015)
CAS  PubMed  PubMed Central  Google Scholar 
38. Niu, Y. et al. Generation of gene-modified cynomolgus
monkey via Cas9/RNA-mediated gene targeting in one-cell
embryos. Cell 156, 836–843 (2014)
CAS  PubMed  Google Scholar 
39. Kang, Y. et al. CRISPR/Cas9-mediated Dax1 knockout in the


monkey recapitulates human AHC-HH. Hum. Mol. Genet. 24,
7255–7264 (2015)
CAS  PubMed  Google Scholar 
40. Liang, P. et al. CRISPR/Cas9-mediated gene editing in human
tripronuclear zygotes. Protein Cell 6, 363–372 (2015)
CAS  PubMed  PubMed Central  Google Scholar 
41. Tu, Z. et al. Promoting Cas9 degradation reduces mosaic
mutations in non-human primate embryos. Sci. Rep. 7, 42081
(2017)
ADS  CAS  PubMed  PubMed Central  Google Scholar 
42. Hashimoto, M., Yamashita, Y. & Takemoto, T. Electroporation
of Cas9 protein/sgRNA into early pronuclear zygotes
generates non-mosaic mutants in the mouse. Dev. Biol. 418,
1–9 (2016)
CAS  PubMed  Google Scholar 
43. Orthwein, A. et al. Mitosis inhibits DNA double-strand break
repair to guard against telomere fusions. Science 344, 189–
193 (2014)
ADS  CAS  PubMed  Google Scholar 
44. Tachibana, M. et al. Towards germline gene therapy of
inherited mitochondrial diseases. Nature 493, 627–631
(2013)
ADS  CAS  PubMed  Google Scholar 
45. Kim, J. M., Kim, D., Kim, S. & Kim, J. S. Genotyping with
CRISPR–Cas-derived RNA-guided endonucleases. Nat.
Commun. 5, 3157 (2014)
ADS  PubMed  Google Scholar 
46. Bae, S., Park, J. & Kim, J. S. Cas-OFFinder: a fast and versatile


algorithm that searches for potential off-target sites of Cas9
RNA-guided endonucleases. Bioinformatics 30, 1473–1475
(2014)
CAS  PubMed  PubMed Central  Google Scholar 
47. Park, J., Lim, K., Kim, J. S. & Bae, S. Cas-analyzer: an online
tool for assessing genome editing results using NGS data.
Bioinformatics 33, 286–288 (2017)
CAS  PubMed  Google Scholar 
48. Raczy, C. et al. Isaac: ultra-fast whole-genome secondary
analysis on Illumina sequencing platforms. Bioinformatics 29,
2041–2043 (2013)
CAS  PubMed  Google Scholar 
Download references
Acknowledgements
We acknowledge the OHSU Institutional Review Board (IRB),
Innovative Research Advisory Panel (IRAP), Scientific Review
Committee (SRC) and Data Safety Monitoring Committee (DSMC)
for oversight and guidance on this study. We thank all study
participants for tissue donations; the Women’s Health Research Unit
staff, IVF laboratory staff, University Fertility Consultants and the
Reproductive Endocrinology and Infertility Division in the
Department of Obstetrics and Gynecology, OHSU for support and
procurement of human gametes; S. Olson and Research
Cytogenetics Laboratory at OHSU for cytogenetic analysis of ES
cells; S. Cooper from the Wallace Division of Smiths Medical for
donating ICSI and gamete manipulation micropipettes; Y. Wang, T.
Wu and Y. Shen from BGI-Shenzhen for help with sample
preparation, sequencing and data analyses; M. Ku from the H. A.
and Mary K. Chapman Charitable Foundations Genomic Sequencing
Core of the Salk Institute for next generation sequencing; and E.
Aizawa and R. Hernandez-Benitez from the laboratory of JCIB for


assistance. Studies conducted at OHSU were supported by OHSU
institutional funds. Work in the laboratory of J.-S.K. was supported
by the Institute for Basic Science (IBS-R021-D1). Work in the
laboratory of J.C.I.B. was supported by the G. Harold and Leila Y.
Mathers Charitable Foundation, the Moxie Foundation and the
Leona M. and Harry B. Helmsley Charitable Trust. Work at BGI was
supported by the Shenzhen Municipal Government of China (DRC-
SZ [2016] 884).
Author information
Author notes
1. Hong Ma, Nuria Marti-Gutierrez, Sang-Wook Park and Jun
Wu: These authors contributed equally to this work.
2. Juan Carlos Izpisua Belmonte, Paula Amato, Jin-Soo Kim,
Sanjiv Kaul and Shoukhrat Mitalipov: These authors jointly
supervised this work.
Authors and Affiliations
1. Center for Embryonic Cell and Gene Therapy, Oregon Health
& Science University, 3303 Southwest, Bond Avenue,
Portland, 97239, Oregon, USA
Hong Ma, Nuria Marti-Gutierrez, Yeonmi Lee, Amy
Koski, Dongmei Ji, Tomonari Hayama, Riffat Ahmed, Hayley
Darby, Crystal Van Dyken, Ying Li, Eunju Kang, David
Battaglia, Don P. Wolf, Paula Amato & Shoukhrat Mitalipov
2. Center for Genome Engineering, Institute for Basic Science,
70, Yuseong-daero 1689-gil, Yuseong-gu, 34047, Daejeon,
Republic of Korea
Sang-Wook Park, A.-Reum Park, Sang-Tae Kim & Jin-Soo Kim
3. Gene Expression Laboratory, Salk Institute for Biological
Studies, 10010 North Torrey Pines Road, La Jolla, 92037,


California, USA
Jun Wu, Keiichiro Suzuki & Juan Carlos Izpisua Belmonte
4. Department of Chemistry, Seoul National University, 599
Gwanak-ro, Gwanak-gu, 151-747, Seoul, Republic of Korea
Daesik Kim & Jin-Soo Kim
5. BGI-Shenzhen, Build 11, Beishan Industrial Zone, Yantian
District, 518083, Shenzhen, China
Jianhui Gong, Ying Gu & Xun Xu
6. China National GeneBank, BGI-Shenzhen, Jinsha Road,
Dapeng District, 518210, Shenzhen, China
Jianhui Gong, Ying Gu & Xun Xu
7. BGI-Qingdao, 2877 Tuanjie Road, Sino-German Ecopark,
Qingdao, 266000, China
Jianhui Gong, Ying Gu & Xun Xu
8. Shenzhen Engineering Laboratory for Innovative Molecular
Diagnostics, BGI-Shenzhen, Build 11, Beishan Industrial Zone,
Yantian District, 518083, Shenzhen, China
Jianhui Gong
9. Division of Reproductive Endocrinology and Infertility,
Department of Obstetrics and Gynecology, Oregon Health &
Science University, 3303 Southwest, Bond Avenue, Portland,
97239, Oregon, USA
David Battaglia, Sacha A. Krieg, David M. Lee, Diana H.
Wu & Paula Amato
10. Knight Cardiovascular Institute, Oregon Health & Science
University, 3181 Southwest, Sam Jackson Park Road,
Portland, 97239, Oregon, USA


Stephen B. Heitner, Sanjiv Kaul & Shoukhrat Mitalipov
Authors
1. Hong Ma
View author publications
Search author on:PubMed Google Scholar
2. Nuria Marti-Gutierrez
View author publications
Search author on:PubMed Google Scholar
3. Sang-Wook Park
View author publications
Search author on:PubMed Google Scholar
4. Jun Wu
View author publications
Search author on:PubMed Google Scholar
5. Yeonmi Lee
View author publications
Search author on:PubMed Google Scholar
6. Keiichiro Suzuki
View author publications
Search author on:PubMed Google Scholar
7. Amy Koski
View author publications
Search author on:PubMed Google Scholar
8. Dongmei Ji
View author publications
Search author on:PubMed Google Scholar


9. Tomonari Hayama
View author publications
Search author on:PubMed Google Scholar
10. Riffat Ahmed
View author publications
Search author on:PubMed Google Scholar
11. Hayley Darby
View author publications
Search author on:PubMed Google Scholar
12. Crystal Van Dyken
View author publications
Search author on:PubMed Google Scholar
13. Ying Li
View author publications
Search author on:PubMed Google Scholar
14. Eunju Kang
View author publications
Search author on:PubMed Google Scholar
15. A.-Reum Park
View author publications
Search author on:PubMed Google Scholar
16. Daesik Kim
View author publications
Search author on:PubMed Google Scholar
17. Sang-Tae Kim
View author publications


Search author on:PubMed Google Scholar
18. Jianhui Gong
View author publications
Search author on:PubMed Google Scholar
19. Ying Gu
View author publications
Search author on:PubMed Google Scholar
20. Xun Xu
View author publications
Search author on:PubMed Google Scholar
21. David Battaglia
View author publications
Search author on:PubMed Google Scholar
22. Sacha A. Krieg
View author publications
Search author on:PubMed Google Scholar
23. David M. Lee
View author publications
Search author on:PubMed Google Scholar
24. Diana H. Wu
View author publications
Search author on:PubMed Google Scholar
25. Don P. Wolf
View author publications
Search author on:PubMed Google Scholar
26. Stephen B. Heitner


View author publications
Search author on:PubMed Google Scholar
27. Juan Carlos Izpisua Belmonte
View author publications
Search author on:PubMed Google Scholar
28. Paula Amato
View author publications
Search author on:PubMed Google Scholar
29. Jin-Soo Kim
View author publications
Search author on:PubMed Google Scholar
30. Sanjiv Kaul
View author publications
Search author on:PubMed Google Scholar
31. Shoukhrat Mitalipov
View author publications
Search author on:PubMed Google Scholar
Contributions
S.M., S.K., Y.Le., N.M.-G. and H.M. conceived the study and
designed the experiments. S.-W.P., J.-S.K. and K.S. designed
CRISPR–Cas9 constructs. A.K., S.B.H. and S.K. coordinated
recruitment of gamete donors. Y.Le. and R.A. derived patient iPSCs
and S.-W.P., J.W.,.K.S and J.C.I.B. tested the specificity of the
CRISPR–Cas9 systems in patient iPSCs. P.A., D.B., D.M.L., S.A.K.
and D.H.W. conducted ovarian stimulation and oocyte retrieval.
N.M.-G., Y.Le., D.J. and T.H. performed CRISPR–Cas9 injections,
fertilizations, embryo culture and blastomere isolation experiments.
N.M.-G., D.J., H.D., C.V.D., Y.Li and E.K. performed DNA
extraction, PCR and Sanger sequencing. S.-W.P., A.-R.P., D.K., S.-


T.K. and J.-S.K. performed Digenome-seq, WGS and analyses and
independently corroborated embryo on-target editing by deep
sequencing. J.G., Y.G., X.X. and J.W. performed whole-exome
sequencing and analyses. H.M., N.M.-G., S.-W.P., J.W., A.K., D.P.W.,
S.B.H., J.C.I.B., P.A., J.-S.K., S.K. and S.M. analysed the data and
wrote the manuscript.
Corresponding authors
Correspondence to Juan Carlos Izpisua Belmonte, Paula Amato, Jin-
Soo Kim, Sanjiv Kaul or Shoukhrat Mitalipov.
Ethics declarations
Competing interests
J.-S.K. is a co-founder and shareholder of ToolGen, Inc, and S.M. is
a co-founder and shareholder of Mitogenome Therapeutics, Inc and
Health and Science Center “M1” Inc and declare competing
financial interests. The other authors declare no competing financial
interests.
Additional information
Reviewer Information Nature thanks F. Lanner and the other
anonymous reviewer(s) for their contribution to the peer review of
this work.
Publisher's note: Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional affiliations.
Extended data figures and tables
Extended Data Figure 1 CRISPR–Cas9 design and


testing in patient iPSCs.
a, b, Schematic of CRISPR–Cas9-1 and CRISPR–Cas9-2 constructs.
Both systems consist of a single-chain chimaeric sgRNA designed to
target the MYBPC3∆GAGT deletion and Cas9 protein. Exogenous
single-stranded oligodeoxynucleotide (ssODN) templates encoding
homology arms to the targeted region were designed for each
system to facilitate HDR. Synonymous single-nucleotide
substitutions were introduced into each ssODN template as
indicated by red letters. Underline in 1a represents wild-type
sequence of 4-bp deletion in the ssODN-1. In addition, the ssODN-2
nucleotide substitutions provide a restriction enzyme (BstBI)
recognition site as indicated with black open box. c, Patient iPSCs
were transfected with CRISPR–Cas9 plasmids by electroporation
and individual single iPSC clones were analysed. d, Representative
chromatographs showing untargeted iPSC clone with heterozygous
mutant (left), targeted iPSC clone with gene corrected via HDR
using ssODN-2 as repair template (middle) and targeted iPSC clone
with gene corrected via HDR using wild-type sequence as template.
e, Targeting and HDR efficiency comparison between CRISPR–
Cas9-1 and CRISPR–Cas9-2. The asterisk indicates a significantly
higher targeting efficiency of CRISPR–Cas9-1 compared to CRISPR–
Cas9-2 (P < 0.05) by one-tailed Fisher’s test. For source data, see
Supplementary Table 1. f, HDR and NHEJ efficiency in wild-type ES
cells (H9) and patient iPSCs transfected with preassembled Cas9
ribonucleoproteins (RNPs).
Extended Data Figure 2 Differences in DNA repair
responses in human embryos and iPSCs and
independent validation of on-target genotyping.
a, Different HDR-based DNA repair was observed in patient
embryos compared to iPSCs. In human embryos, induced DSBs in
the mutant paternal gene were repaired exclusively using the wild-
type maternal allele as a template. In striking contrast, HDR in
iPSCs was directed by the external ssODN-1 template. b,
Verification of blastomere on-target genotypes by deep sequencing.
DNA samples from 86 individual blastomeres representing different
treatments and controls were sequenced using the MiSeq platform.


Total reads, wild-type reads and mutant reads are presented as a
mean. Distribution of mutant reads in heterozygous (34.3–64%) or
homozygous (0.01–0.1%) blastomeres in experimental embryos was
similar to controls.
Extended Data Figure 3 Genetic stability of ES cells
derived from CRISPR–Cas9-injected embryos.
a, Origin and genotypes of ES cells derived from CRISPR–Cas9-
injected embryos. b, Karyotype of ES-WT3 showing a pericentric
inversion on chromosome 10. c, Magnified image showing normal
(left chromosome) and inverted chromosome 10 (right
chromosome, inverted region indicated by arrow). d, Chromosome
10 ideogram showing the location of the inversion.
Extended Data Figure 4 Digenome sequencing of
potential off-target sites.
a, Representative Integrative Genomics Viewer (IGV) images
produced using CRISPR–Cas9 at the on-target site. b, Representative
IGV images showing CRISPR–Cas9-induced DNA cleavage at the
potential off-target sites. Red arrows indicate DNA cleavage sites at
each off-target site.
Extended Data Figure 5 Digenome-seq based off-target
mutation screening of treated human embryos.
a, Genome-wide Circos plots showing DNA cleavage scores. Cas9-
only-treated DNA is shown in grey, and CRISPR–Cas9-treated DNA
is in blue. b, Sequence logo obtained via WebLogo using Digenome-
captured sites (DNA cleavage score >2.5). On-target sequence is
indicated below the sequence logo. PAM sequence is shown in blue.
c, On-target indels for 28 blastomeres detected by Digenome-seq.
Only blastomeres carrying NHEJ were captured by Digenome-seq.
Blastomeres indicated in red fonts were also analysed by WGS
(Extended Data Table 6). d, Indel frequencies for potential off-target
sites captured by Digenome-seq in CRISPR–Cas9-treated (n = 5) and
untreated control embryos (n = 2). Mismatch nucleotides are shown
in red. PAM sequence is shown in blue. OnT: on target site; OT: off-


target. Percentages of mutagenic indels on the x-axis are presented
on a logarithmic scale. For source data, see Supplementary Table 5.
Extended Data Figure 6 WES analysis of ES cell lines
derived from CRISPR–Cas9-injected embryos.
a, SNP and indel fractions of variants identified in each sample
presented in dbSNP and 1000genomes databases. b, Numbers of
coding region variants (SNPs) in each sample divided into indicated
categories. c, Numbers of coding region variants (indels) divided
into indicated categories. Hg19 was used as a reference genome for
variant calling. Data presented as mean with interquartile range
(black horizontal bars). For source data, see Supplementary Tables
6–8.
Extended Data Table 1 DNA oligo sequences used for CRISPR–
Cas9-based gene correction
Full size table
Extended Data Table 2 Preimplantation development of human
oocytes and zygotes after CRISPR–Cas9 injection
Full size table
Extended Data Table 3 Genotypes of blastomeres in mosaic
human embryos produced by CRISPR–Cas9 injection into
zygotes
Full size table
Extended Data Table 4 List of potential off-target sites captured
by Digenome-seq
Full size table
Extended Data Table 5 List of PCR primers used in targeted
deep sequencing
Full size table
Extended Data Table 6 Analysis of off-target effects in CRISPR–
Cas9-injected human embryos by WGS
Full size table
Related audio
Reporter Shamini Bundell investigates a new


development in the gene editing of human embyos
Supplementary information
Reporting summary
Supplementary Table 1
Genotypes of individual iPSC clones
Supplementary Table 2
Genotypes of individual blastomeres in control embryos
Supplementary Table 3
Genotypes of individual blastomeres in zygote injected embryos
Supplementary Table 4
Genotypes of individual blastomeres in M-phase injected embryos
Supplementary Table 5
Mutagenic indel frequencies at potential off-target sites captured by
Digenome-sequencing
Supplementary Table 6
Whole exome sequencing (WES) analyses of variants identified
using Hg19 as reference genome
Supplementary Table 7
List of predicted off-target sites
Supplementary Table 8


WES analyses of non-inherited variants
Video: CRISPR/Cas9 injection into human oocytes
and zygotes
CRISPR/Cas9 injection into human oocytes and zygotes. S-phase
CRISPR/Cas9 injection was performed 18 hours after ICSI. M-phase
injections were co-injected with sperm during ICSI.
PowerPoint slides
PowerPoint slide for Fig. 1
PowerPoint slide for Fig. 2
PowerPoint slide for Fig. 3
PowerPoint slide for Fig. 4
Rights and permissions
Reprints and permissions
About this article
[image]
Cite this article
Ma, H., Marti-Gutierrez, N., Park, SW. et al. Correction of a
pathogenic gene mutation in human embryos. Nature 548, 413–419
(2017). https://doi.org/10.1038/nature23305
Download citation


•  Received: 28 March 2017
•  Accepted: 27 June 2017
•  Published: 02 August 2017
•  Issue date: 24 August 2017
•  DOI: https://doi.org/10.1038/nature23305
Share this article
Anyone you share the following link with will be able to read this
content:
Get shareable link
Sorry, a shareable link is not currently available for this article.
Copy shareable link to clipboard
Provided by the Springer Nature SharedIt content-sharing initiative
This article is cited by
•  From gut to gamete: how the microbiome
influences fertility and preconception health
○  Sarah K. Munyoki
○  Natalie Vukmer
○  Eldin Jašarević
Microbiome (2025)
•  Non-viral generation of transgenic non-human
primates via the piggyBac transposon system
○  Masataka Nakaya


○  Chizuru Iwatani
○  Tomoyuki Tsukiyama
Nature Communications (2025)
•  Discussions on Human Enhancement Meet
Science: A Quantitative Analysis
○  Tomasz Żuradzki
○  Piotr Bystranowski
○  Vilius Dranseika
Science and Engineering Ethics (2025)
•  Precision medicine in the management of cardiac
arrhythmias
○  Felix Wiedmann
○  Constanze Schmidt
Herz (2025)
•  Methyl β-Cyclodextrin-sperm-mediated gene
editing (MBCD-SMGE): a simple and efficient
method for targeted mutant mouse production
○  Parisa Moradbeigi
○  Sara Hosseini
○  Asghar Mogheiseh
Biological Procedures Online (2024)
Comments
Commenting on this article is now closed.
1. Fernando Aleman 2 August 2017, 23:11
I think the analysis of off-targets by WGS is very poor:


1.- Since previous studies (http://www.nature.com/nmeth...
indicate SNVs are the most common off-target mutation, why
?dbSNPs and all novel SNPs? were filtered out?
2.- Why do authors need to cherry pick the ?potential? off-
targets with Cas-OFFinder when the main purpose of the WGS
is a non-biased finder of genetic variants?
3.- Without disclosing the whole sequence (understandable
patient confidentiality), authors could show how they
discarded the selected ?potential? off-targets (lanes 4 and 7
from Extended Data Table 6) ?by inspecting sequences with
Integrative Genomics Viewer?. Even a simple screenshot of
those loci might disperse doubts about the method to account
for ?poly-A or poly-GT repeats? and reaffirm than those were
really ?caused by sequencing errors rather than Cas9-
catalysed?.
4.- ?We found 19?71 potential off-target sites with indels in
each blastomere obtained from CRISPR?Cas9-injected
embryos (lanes 4 and 7 in Extended Data Table 6).? But those
numbers are not the ones I see in the table.
5.- Continuing with the Extended Data of Table 6, it is
striking to see that the ratios of ?excluded? dbSNPs is
significantly higher for the CRISPR samples than for the 2
controls. While 5.6 and 3.8% of dbSNPs were analyzed for the
controls (and these will further be used as excluders later in
the analysis), only from 2.5 to 1.5% of total dbSNPs were
further analyzed in CRISPR samples. Also, the sample with
more excluded dbSNPs is the one with more ?potential? off-
targets fished by Cas-OFFinder.
In summary, too many parameters have been used to filter
out off-targets and get to the conclusion that there were no ?
detectable off-target mutations in selected blastomeres?.
2. Paul Knoepfler 3 August 2017, 14:19
I've done a journal club kind of style review of this paper and
tried to place it in a bigger picture of societal and ethical
concerns here: http://bit.ly/2vtKFPu. In short, great science
here, but still a long way to do such as reducing Indels to
near zero, being surer about off-targets, testing on embryos
from a range of gamete donors, etc. plus hefty societal and


bioethical issues we are all still trying to work through at this
point.
Paul
3. Wiii 2 January 2018, 00:51
I can't wait for this tool to remove HCM gene from me ASAP.
 Access through your institution
Buy or subscribe
show all
Editorial Summary
CRISPR-corrected mutation
Genome editing could be applied to correct disease-causing
mutations in human embryos, but concerns about efficacy and
safety are paramount. Shoukhrat Mitalipov and colleagues use
CRISPR–Cas9 to correct a heritable cardiomyopathy mutation in
human embryos. By optimizing the experimental conditions, the
authors show very reduced mosaicism, and report that for this
heterozygous mutation, CRISPR–Cas9-induced breaks seem to be
preferentially repaired using the wild-type allele as a template in
human embryos. The results advance our understanding of the
promises and challenges of editing the human germline.
Associated content
At the heart of gene edits in human embryos
•  Nerges Winblad
•  Fredrik Lanner
Nature News & Views 02 Aug 2017


Advertisement
[image]
Explore content
•  Research articles
•  News
•  Opinion
•  Research Analysis
•  Careers
•  Books & Culture
•  Podcasts
•  Videos
•  Current issue
•  Browse issues
•  Collections
•  Subjects
•  Follow us on Facebook
•  Follow us on Twitter
•  Subscribe
•  Sign up for alerts
•  RSS feed
About the journal
•  Journal Staff
•  About the Editors
•  Journal Information
•  Our publishing models
•  Editorial Values Statement
•  Journal Metrics
•  Awards
•  Contact
•  Editorial policies


•  History of Nature
•  Send a news tip
Publish with us
•  For Authors
•  For Referees
•  Language editing services
•  Open access funding
•  Submit manuscript
Search
Search articles by subject, keyword or author
Show results from All journals This journal
Search
Advanced search
Quick links
•  Explore articles by subject
•  Find a job
•  Guide to authors
•  Editorial policies
Nature (Nature)
ISSN 1476-4687 (online)
ISSN 0028-0836 (print)
nature.com sitemap
About Nature Portfolio


•  About us
•  Press releases
•  Press office
•  Contact us
Discover content
•  Journals A-Z
•  Articles by subject
•  protocols.io
•  Nature Index
Publishing policies
•  Nature portfolio policies
•  Open access
Author & Researcher services
•  Reprints & permissions
•  Research data
•  Language editing
•  Scientific editing
•  Nature Masterclasses
•  Research Solutions
Libraries & institutions
•  Librarian service & tools
•  Librarian portal
•  Open research
•  Recommend to library
Advertising & partnerships
•  Advertising
•  Partnerships & Services
•  Media kits
•  Branded content


Professional development
•  Nature Awards
•  Nature Careers
•  Nature Conferences
Regional websites
•  Nature Africa
•  Nature China
•  Nature India
•  Nature Japan
•  Nature Middle East
•  Privacy Policy
•  Use of cookies
•  Your privacy choices/Manage cookies
•  Legal notice
•  Accessibility statement
•  Terms & Conditions
•  Your US state privacy rights
[image]
© 2025 Springer Nature Limited


 Close
[image]
Sign up for the Nature Briefing newsletter — what matters in
science, free to your inbox daily.
Email address


Sign up
I agree my information will be processed in accordance with the
Nature and Springer Nature Limited Privacy Policy.
 Close
Get the most important science stories of the day, free in your
inbox. Sign up for Nature Briefing
[image]


